Generic Name: glucagon
Brand Name: TBC
Manufacturer: Eli Lilly Canada Inc.
Indications: Severe hypoglycemic reactions
Manufacturer Requested Reimbursement Criteria1: For the treatment of severe hypoglycemic reactions which may occur in the management of insulin treated adult and pediatric patients with diabetes mellitus, when impaired consciousness precludes oral carbohydrates.
Submission Type: New
Project Status: Active
Companion Diagnostics: No
Fee Schedule: Schedule A
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
|Call for patient input posted||June 25, 2019|
|Patient group input closed||August 15, 2019|
|Patient input summary sent for review to patient input groups||-|
|Patient group comments on input summary closed||-|
|Submission received||July 24, 2019|
|Submission accepted for review||August 08, 2019|
|Review initiated||August 09, 2019|
|Draft CADTH review report(s) sent to applicant||October 24, 2019|
|Comments from applicant on draft CADTH review report(s) received||November 04, 2019|
|CADTH review team's comments on draft CADTH review report(s) sent to applicant||November 29, 2019|
|Canadian Drug Expert Committee (CDEC) meeting||December 11, 2019|
|CDEC recommendation sent to applicant and drug plans||December 23, 2019|
January 02, 2020